Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO

Rhea-AI Summary

Tentarix Biotherapeutics appoints Andrew D. Kidd, MD, CFA, as CEO, leveraging his extensive executive and biotech experience. Mr. Kidd, formerly president and CEO of Aptinyx, brings a wealth of knowledge to lead Tentarix in its mission to revolutionize patient care through multi-specific biologic treatments. The company aims to advance existing programs with Gilead and AbbVie while rapidly developing its internal pipeline under Mr. Kidd's leadership.

SAN DIEGO--(BUSINESS WIRE)-- Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience. He was most recently the president and CEO of Aptinyx (NASDAQ: APTX), a clinical-stage CNS-focused biotech company. His previous experience includes senior leadership roles at Baxter International (NYSE: BAX) and The Boston Consulting Group.

“We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company,” said Tentarix Chairman Donald Santel. “Under Andy’s leadership, we are poised to effectively execute on our existing partnered programs with Gilead and AbbVie, and to rapidly build and advance our internal pipeline of programs in the near-term.”

"I am honored to join Tentarix at such a pivotal time in its journey," said Mr. Kidd. "I firmly believe in the company's mission to revolutionize patient care through multi-specific biologic treatments. The compelling science behind the Tentacles™ platform presents an unparalleled opportunity to impact the lives of patients globally. I am committed to harnessing this potential, driving forward our strategic initiatives, and building on the strong foundation laid by the Tentarix team to deliver on our promise of transforming the landscape of precision oncology and immunology."

About Tentarix Biotherapeutics: Tentarix's mission is to develop first-in-class targeted, multifunctional, conditional therapies across a range of indications of high unmet medical need. Tentarix is focused on modulating cell specific functions while increasing the safety profile for biologics. Tentarix has built a team that aims to transform research and development through understanding complex immune interactions (CellSurf™), discovery of novel human antibodies (HuTARG™), and high-throughput screening of conditional multi-specifics (FunctionSeq™). For more information, please visit www.tentarix.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240423691725/en/

Brady Johnson

IR@tentarix.com

Source: Tentarix Biotherapeutics

FAQ

Who is the new CEO of Tentarix Biotherapeutics?

Andrew D. Kidd, MD, CFA, is the new CEO of Tentarix Biotherapeutics.

What is the previous position of Andrew Kidd, the new CEO of Tentarix Biotherapeutics?

Andrew Kidd was previously the president and CEO of Aptinyx.

What companies did Andrew Kidd have senior leadership roles in before joining Tentarix Biotherapeutics?

Before Tentarix Biotherapeutics, Andrew Kidd had senior leadership roles at Baxter International and The Boston Consulting Group.

What are the key responsibilities of the new CEO, Andrew Kidd, at Tentarix Biotherapeutics?

The new CEO, Andrew Kidd, is tasked with executing existing partnered programs with Gilead and AbbVie, advancing the internal pipeline, and driving strategic initiatives for precision oncology and immunology.